This afternoon, Action Duchenne has since had confirmation by the Santhera team and this article that this decision has no consequences on their …
Update on CHMP negative opinion for Raxone (idebenone)Read More
First person reaches 15 month mark through Phrixus’ Carmseal-MD
Phrixus Pharmaceuticals has announced that the first person living with Duchenne has completed 15 months of treatment with Carmeseal-MD. The …
First person reaches 15 month mark through Phrixus’ Carmseal-MDRead More
Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines
Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function in the canine model (dogs). …
Parallel 2017 was amazing!
Parallel London 2017 was an absolutely inspirational day! 60 incredible people took part for Action Duchenne, representing the entire community, …
Sarconeos announced as new potential treatment for Duchenne
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy An abstract …
Sarconeos announced as new potential treatment for DuchenneRead More
Breaking news – first people enrolled in Raxone EAMS scheme in UK
We are delighted to announce the first people are enrolled in the UK's Early Access to Medicines Scheme (EAMS) for Raxone. Janet Bloor, Chair of …
Breaking news – first people enrolled in Raxone EAMS scheme in UKRead More
Action Duchenne are Delighted to Announce Our New Campaigns Officer: Kathy
Kathy Wedell, mother to Isaac, is Action Duchenne's new Campaigns Officer "On World Duchenne Awareness Day I’m delighted to announce that …
Action Duchenne are Delighted to Announce Our New Campaigns Officer: KathyRead More
Action Duchenne invites the participation of the Becker muscular dystrophy community in November!
On Friday 10 November 2017, the first day of our new and extended international conference will be dedicated to new horizons in pre-clinical research …
NICE Consultation on Guidelines for Suspected Neurological Conditions
NICE (the National Institute for Health and Care Excellence) have released for consultation, a new set of draft guidelines for healthcare …
NICE Consultation on Guidelines for Suspected Neurological ConditionsRead More
Pharmaceutical Companies Working in Duchenne Report Q2 Financial Results and Provide Business Updates
A number of pharmaceutical and biotech companies working in the field of Duchenne muscular dystrophy, have recently reported their 2nd quarter …
Portrait of Duchenne – Ravi’s good life
In the seventh interview in the “Portrait of Duchenne” series, our Canadian partners, La Force talked with Ravi Mehta at the Action …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is Developed
Researchers at Cardiff University, in collaboration with biotechnology company PerkinElmer, have created a more reliable test to screen newborn babies …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is DevelopedRead More
